Join the Bipolar Disorder group to help and get support from people like you.
Bipolar Disorder News (Page 3)
Related terms: Bipolar Affective Disorder, Bipolar Affective Mood Disorder, Bipolar I Disorder, Manic Depression, Manic Depressive Disorder, Manic Depressive Illness, Mood Disorder, Bipolar, Bipolar Depression, Ultra Rapid Cycling, Bipolar II Disorder
Few Doctors, Spotty Internet: Finding Mental Health Care Tough for Many Americans
WEDNESDAY, Sept. 20, 2023 – Nearly one in five counties across the United States lack psychiatrists or internet service, making it difficult for around 10.5 million Americans to find mental health...
Meeting At-Risk Criteria Increases Risk for Transition to Bipolar Disorder
WEDNESDAY, Sept. 20, 2023 – Patients meeting bipolar at-risk (BAR) criteria are significantly more likely to transition to bipolar disorder (BD) during the next decade versus patients seeking mental...
Dialectical Behavior Therapy Tied to Fewer Suicide Attempts
TUESDAY, Sept. 19, 2023 – Dialectical behavior therapy (DBT) is effective for decreasing suicide attempts among adolescents with bipolar spectrum disorder, according to a study published online...
Smoking Increases Risk for Mental Illness
TUESDAY, Sept. 5, 2023 – Smoking increases the risk for developing mental disorders, according to a study published online Aug. 21 in Acta Psychiatrica Scandinavica. Lloyd Balbuena, from University...
Extended Use of Antidepressants May Help People With Bipolar Disorder
THURSDAY, Aug. 10, 2023 – Modern antidepressants could be effective for long-term treatment of some patients with bipolar disorder, a new trial suggests. Current guidelines discourage use of...
Prolonged Antidepressant Treatment No Benefit in Bipolar I Disorder
THURSDAY, Aug. 3, 2023 – For patients with bipolar I disorder who had recently had remission of a depressive episode, adjunctive treatment with escitalopram or bupropion XL that continues for 52...
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
April 28, 2023 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA)...
FDA Approves Rykindo (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Bipolar 1 Disorder
PRINCETON, N.J., Jan. 15, 2023 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, today ...
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for Caplyta (lumateperone) for Specific Patient Populations
Caplyta label now includes dosage recommendations for specific patient populations; those with moderate or severe hepatic impairment and patients who are concomitantly taking moderate or strong...
FDA Approves Igalmi (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
NEW HAVEN, Conn., April 06, 2022 (GLOBE NEWSWIRE) – BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop...
Intra-Cellular Therapies Announces U.S. FDA Approval of Caplyta (lumateperone) for the Treatment of Bipolar Depression in Adults
Caplyta is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or...
FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder
DUBLIN, June 1, 2021 /PRNewswire/ – Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Lybalvi (olanzapine and samidorphan) for the treatment...
FDA Approves Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression
DUBLIN and BUDAPEST, Hungary, May 28, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a...
FDA Medwatch Alert: Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction
ISSUE: The FDA is warning that the medicine Lamictal (lamotrigine) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s i...
FDA Approves Latuda (lurasidone HCl) for Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- March 6, 2018 – Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
gabapentin, sertraline, clonazepam, Seroquel, citalopram, escitalopram, bupropion, Lamictal, Abilify, view more... venlafaxine, lithium, lamotrigine, duloxetine, Latuda, Depakote, quetiapine, topiramate, clonidine, Vraylar, olanzapine, risperidone, Zyprexa, Risperdal, aripiprazole, Seroquel XR, Geodon, desvenlafaxine, oxcarbazepine, verapamil, levetiracetam